After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.